The FDA has approved Nucala (mepolizumab) for the add-on maintenance treatment of patients with inadequately controlled eosinophilic COPD.

Nucala's approval offers hope for uncontrolled COPD. This new drug reduces flare-ups, a key benefit for Black Americans.

A COPD treatment for former smokers developed by Regeneron Pharmaceuticals and Sanofi failed to meet its primary endpoint in ...

Results released Friday show itepekimab succeeded in one Phase 3 trial but failed in a second, sinking shares of both partner ...

Uncover the truth behind Breathe Supplement with our full reviews—learn if this herbal lung formula is safe, effective, and ...

Long-term oxygen therapy (LTOT) is linked to reduced exacerbations and hospitalizations in COPD, ILD, and pulmonary hypertension.

Breathe easier with this natural supplement. See how Breathe Drops aid in clearing airways and boosting lung function—plus ...

MUSC Health Florence Medical Center has spearheaded the introduction of an advanced aerosol delivery system – one that is now transforming how respiratory patients receive breathing treatments in ...

The approval tees GSK up to challenge Sanofi and Regeneron, which in September 2024 won the first biologic approval for COPD ...

GSK respiratory, immunology and inflammation research and development (R&D) global head and senior vice-president Kaivan ...

GSK plc GSK announced that the FDA has approved its blockbuster respiratory drug, Nucala (mepolizumab), for a fifth ...

The U.S. Food and Drug Administration has approved GSK plc (NYSE: GSK )’s asthma medication, Nucala, for expanded use in ...